Remove 2018 Remove Access Remove Clinical Trials Remove Patients
article thumbnail

UK: David Hardstaff And John Binns Write For Open Access Government Exploring Shifting Sands In The UK CBD Industry

Cannabis Law Report

One of the largest and arguably sustainable customer bases, however, is consumers with some sort of health or therapeutic need for which they are unable to access medicinal cannabis. One potential consequence of the FSA’s drive to rein in the UK’s CBD industry is reduced access to the previously available wide range of products.

Access 52
article thumbnail

The “Right to Try” Psilocybin and New Drug Therapies

Canna Law Blog

We discussed how licensed facilities won’t be up and running for a few more years, and how, in the meantime, people will have to make do with general decriminalization under Measure 109 and maybe, in certain cases, reliance on Right to Try access. It’s quite restrictive. Or, it could be because FDA is sort of a drag about everything.

Therapy 82
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Article: Cannabis & CBD Pharma NewsNews Does medicinal cannabis actually help Australian patients?

Cannabis Law Report

There have been more than 7,500 approvals for medicinal cannabis in Australia since legalisation in 2016 – so why don’t we know if it is helping patients? Access to medicinal cannabis for patients was legalised in Australia in 2016, allowing doctors to request permission to prescribe from the Australian government.

article thumbnail

Understanding the Current Legal Status of Psychedelics in the United States

Cannabis Law Report

The first path, that of traditional medicine, currently offers patients limited options. The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. 2022 Active FDA Clinical Trials and State-Regulated Systems.

article thumbnail

Press Release: COMPASS Pathways joins forces with King’s College London and South London and Maudsley NHS Foundation Trust to accelerate psychedelic research and develop new models of mental health care in the UK

Cannabis Law Report

David Bradley, Chief Executive of South London and Maudsley NHS Foundation Trust, said, “We believe this collaboration could accelerate much-needed research that will translate into evidence-based and direct patient care for people who use our services. London, UK – 5 July 2021.

article thumbnail

The Science Behind Medical Marijuana: Exploring Cannabinoids and Their Therapeutic Effects

MMJ Recs

These compounds may help reduce symptoms and improve the quality of life for patients. Cannabis Research and Patient Outcomes The scientific exploration of cannabinoids and their therapeutic effects has opened the door to numerous research initiatives. The outcomes of these studies have had a profound impact on patient care.

article thumbnail

UK – Press Release: Beckley Psytech Bolsters Pipeline of Next-Generation Psychedelic Medicines With Research Collaboration and Strengthening of Relationship With Lophora ApS

Cannabis Law Report

Lophora has previously secured grant funding from the BioInovation Institute (Novo Nordisk Foundation) and continues to characterise its lead candidates, aiming to initiate clinical trials in 2023. Lophora is a drug-development company founded in 2018 in Copenhagen, Denmark. Lophora – www.lophora.com.